Sugi Predict

Sugi Predict / Compounds / SCHEMBL4456474

SCHEMBL4456474

SCHEMBL4456474

CC(C)C(=O)OCc1ccc(C(C)C)cc1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 2/20 0.55
▸ RXRA P19793 1/20 0.53
▸ RXRB P28702 1/20 0.53
▸ KMT2A Q03164 3/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ LMNA P02545 1/20 0.47
▸ EGFR P00533 1/20 0.46
▸ RAB9A P51151 6/20 0.45
▸ NPC1 O15118 5/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ POLB P06746 1/20 0.45
▸ L3MBTL1 Q9Y468 2/20 0.44
▸ HRH3 Q9Y5N1 1/20 0.43
▸ ALDH1A1 P00352 3/20 0.42
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ NFE2L2 Q16236 1/20 0.42
▸ ROCK2 O75116 1/20 0.42
▸ GRIN2B Q13224 1/20 0.41
▸ HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15762727 0.90 ALDH1A1 (0.48) KMT2AMEN1LMNAKDM4EPOLB
SCHEMBL873057 0.85 ALDH1A1 (0.60) IDO1RXRARXRBKMT2AMEN1
SCHEMBL9976423 0.85 MMP2 (0.51) IDO1KMT2AMEN1LMNAL3MBTL1
SCHEMBL19037277 0.85 LMNA (0.43) IDO1KMT2AMEN1LMNAALDH1A1
SCHEMBL25749660 0.84 IDO1 (0.47) IDO1RXRARXRBKMT2AMEN1
SCHEMBL22319410 0.83 IDO1 (0.53) IDO1RXRARXRBKMT2AMEN1
SCHEMBL13207287 0.83 ALDH1A1 (0.58) IDO1RXRARXRBKMT2AMEN1
SCHEMBL24967267 0.82 ACACB (0.45) KMT2AMEN1LMNANPC1KDM4E
SCHEMBL29339569 0.82 RXRA (0.46) RXRARXRBKMT2AMEN1LMNA
SCHEMBL4457286 0.82 ALDH1A1 (0.48) KMT2AMEN1RAB9ANPC1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024073436-A2 COMPOSITIONS AND USES THEREOF SOLVE THERAPEUTICS, INC. (US) 2024-04-04 — — WO disclosed
US-20230381323-A1 RELEASABLE CONJUGATES FISH & RICHARDSON PC 2023-11-30 — — US disclosed
US-11786599-B2 Releasable conjugates QUIAPEG PHARMACEUTICALS AB (SE) 2023-10-17 — — US disclosed
EP-4223318-A1 ANTITUMOR COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF Duality Biologics (Suzhou) Co., Ltd. (CN) 2023-08-09 — — EP disclosed
US-11692043-B2 Peptidomimetic compounds and antibody-drug conjugates thereof MEDIMMUNE LIMITED (GB) 2023-07-04 — — US disclosed
US-11685742-B2 Anti-tumor compound and preparation method and use thereof DUALITY BIOLOGICS (SUZHOU) CO., LTD. (CN) 2023-06-27 — — US disclosed
US-11685742-B2 Anti-tumor compound and preparation method and use thereof DUALITY BIOLOGICS (SUZHOU) CO., LTD. (CN) 2023-06-27 — — US disclosed
US-11357828-B2 Releasable GLP-1 conjugates QUIAPEG PHARMACEUTICALS AB (SE) 2022-06-14 — — US disclosed
US-20220118055-A1 RELEASABLE GLP-1 CONJUGATES FISH & RICHARDSON PC 2022-04-21 — — US disclosed
US-20210170045-A1 RELEASABLE ANTIBODY CONJUGATES FISH & RICHARDSON PC 2021-06-10 — — US disclosed
US-20200157240-A1 PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF MEDIMMUNE LIMITED (GB) 2020-05-21 — — US disclosed
US-10640507-B2 PBD antibacterial agents KING'S COLLEGE LONDON (GB) 2020-05-05 — — US disclosed
US-20160310611-A1 PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF GENENTECH INC. (US) 2016-10-27 — — US disclosed
US-7638479-B2 3-methylbenzyl-isobutyrate SYMRISE GMBH & CO. KG (DE) 2009-12-29 — — US disclosed
US-20090131299-A1 3-Methylbenzyl-Isobutyrate SYMRISE GMBH & CO. KG (DE) 2009-05-21 — — US disclosed
US-7494967-B2 3-methylbenzyl-isobutyrate SYMRISE GMBH & CO. KG (DE) 2009-02-24 — — US disclosed
US-20070191258-A1 3-Methylbenzyl-isobutyrate SYMRISE GMBH & CO. KG (DE) 2007-08-16 — — US disclosed
US-7163923-B2 Bactericides, fungicides, viricides CELMED ONCOLOGY (USA), INC. (CA) 2007-01-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10640507-B2 PBD antibacterial agents OPRD1, XDH, SBDS IDO1 1027/4885RXRA 210/4885RXRB 187/4885
US-20200157240-A1 PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF DNPEP, LNPEP, VIP IDO1 3334/4885RXRA 3617/4885RXRB 3570/4885
US-20210170045-A1 RELEASABLE ANTIBODY CONJUGATES BCR, CD47, RNASE1 IDO1 4544/4885RXRA 4466/4885RXRB 4482/4885
US-20230381323-A1 RELEASABLE CONJUGATES GUSB, ABCB11, UGT2B7 IDO1 2709/4885RXRA 2497/4885RXRB 1667/4885
US-11685742-B2 Anti-tumor compound and preparation method and use thereof RCC2, REN, VHL IDO1 1034/4885RXRA 3851/4885RXRB 3755/4885
US-11357828-B2 Releasable GLP-1 conjugates GLP1R, GIPR, IAPP IDO1 1698/4885RXRA 1807/4885RXRB 1403/4885
US-20090131299-A1 3-Methylbenzyl-Isobutyrate ABAT, GABRB3, GABBR1 IDO1 1615/4885RXRA 1856/4885RXRB 443/4885
US-11786599-B2 Releasable conjugates GUSB, ABCB11, UGT2B7 IDO1 2709/4885RXRA 2497/4885RXRB 1667/4885
US-20220118055-A1 RELEASABLE GLP-1 CONJUGATES GLP1R, GIPR, IAPP IDO1 1698/4885RXRA 1807/4885RXRB 1403/4885
US-11692043-B2 Peptidomimetic compounds and antibody-drug conjugates thereof DNPEP, LNPEP, VIP IDO1 3334/4885RXRA 3617/4885RXRB 3570/4885
US-20160310611-A1 PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF DNPEP, BCR, LNPEP IDO1 3410/4885RXRA 3608/4885RXRB 3601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.